Switch theme
Sign up to access all valuation multiples
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all of the majority organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.
1998
158
LTM Revenue $91.1M
LTM EBITDA $20.3M
$966M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xvivo Perfusion has a last 12-month revenue (LTM) of $91.1M and a last 12-month EBITDA of $20.3M.
In the most recent fiscal year, Xvivo Perfusion achieved revenue of $84.8M and an EBITDA of $29.8M.
Xvivo Perfusion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xvivo Perfusion valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $91.1M | XXX | $84.8M | XXX | XXX | XXX |
| Gross Profit | $68.3M | XXX | $63.6M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $20.3M | XXX | $29.8M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 35% | XXX | XXX | XXX |
| EBIT | $13.0M | XXX | $9.2M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $13.8M | XXX | $17.8M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Xvivo Perfusion's stock price is SEK 306 (or $32).
Xvivo Perfusion has current market cap of SEK 9.7B (or $996M), and EV of SEK 9.4B (or $966M).
See Xvivo Perfusion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $966M | $996M | XXX | XXX | XXX | XXX | $0.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Xvivo Perfusion has market cap of $996M and EV of $966M.
Xvivo Perfusion's trades at 11.4x EV/Revenue multiple, and 32.4x EV/EBITDA.
Equity research analysts estimate Xvivo Perfusion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xvivo Perfusion has a P/E ratio of 71.9x.
See valuation multiples for Xvivo Perfusion and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $996M | XXX | $996M | XXX | XXX | XXX |
| EV (current) | $966M | XXX | $966M | XXX | XXX | XXX |
| EV/Revenue | 10.6x | XXX | 11.4x | XXX | XXX | XXX |
| EV/EBITDA | 47.5x | XXX | 32.4x | XXX | XXX | XXX |
| EV/EBIT | 74.1x | XXX | 104.7x | XXX | XXX | XXX |
| EV/Gross Profit | 14.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 71.9x | XXX | 56.1x | XXX | XXX | XXX |
| EV/FCF | -73.3x | XXX | -114.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXvivo Perfusion's last 12 month revenue growth is 23%
Xvivo Perfusion's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Xvivo Perfusion's rule of 40 is 51% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xvivo Perfusion's rule of X is 79% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Xvivo Perfusion and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 51% | XXX | 58% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 79% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xvivo Perfusion acquired XXX companies to date.
Last acquisition by Xvivo Perfusion was XXXXXXXX, XXXXX XXXXX XXXXXX . Xvivo Perfusion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Xvivo Perfusion founded? | Xvivo Perfusion was founded in 1998. |
| Where is Xvivo Perfusion headquartered? | Xvivo Perfusion is headquartered in Sweden. |
| How many employees does Xvivo Perfusion have? | As of today, Xvivo Perfusion has 158 employees. |
| Who is the CEO of Xvivo Perfusion? | Xvivo Perfusion's CEO is Mr. Christoffer Rosenblad. |
| Is Xvivo Perfusion publicy listed? | Yes, Xvivo Perfusion is a public company listed on STO. |
| What is the stock symbol of Xvivo Perfusion? | Xvivo Perfusion trades under XVIVO ticker. |
| When did Xvivo Perfusion go public? | Xvivo Perfusion went public in 2012. |
| Who are competitors of Xvivo Perfusion? | Similar companies to Xvivo Perfusion include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Xvivo Perfusion? | Xvivo Perfusion's current market cap is $996M |
| What is the current revenue of Xvivo Perfusion? | Xvivo Perfusion's last 12 months revenue is $91.1M. |
| What is the current revenue growth of Xvivo Perfusion? | Xvivo Perfusion revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Xvivo Perfusion? | Current revenue multiple of Xvivo Perfusion is 10.6x. |
| Is Xvivo Perfusion profitable? | Yes, Xvivo Perfusion is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Xvivo Perfusion? | Xvivo Perfusion's last 12 months EBITDA is $20.3M. |
| What is Xvivo Perfusion's EBITDA margin? | Xvivo Perfusion's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Xvivo Perfusion? | Current EBITDA multiple of Xvivo Perfusion is 47.5x. |
| What is the current FCF of Xvivo Perfusion? | Xvivo Perfusion's last 12 months FCF is -$13.2M. |
| What is Xvivo Perfusion's FCF margin? | Xvivo Perfusion's last 12 months FCF margin is -14%. |
| What is the current EV/FCF multiple of Xvivo Perfusion? | Current FCF multiple of Xvivo Perfusion is -73.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
